

BLUE JET HEALTHCARE LIMITED

REGISTERED & CORPORATE: 701 & 702, BHUMIRAJ COSTARICA, PLOT 1 & 2, SECTOR - 18, SANPADA, NAVI MUMBAI - 400705

T: 022-41840550 / 40037603 F: +91 22 27814204

E: sales@bluejethealthcare.com | CIN NO.: L99999MH1968PLC014154

July 22, 2025

To,

BSE Limited National Stock Exchange of India Limited

Phiroze Jeejebhoy Towers "Exchange Plaza"

Bandra-Kurla Complex, Bandra (East) Dalal Street Mumbai - 400 001

Mumbai – 400051

Scrip Code (BSE): 544009 **Symbol: BLUEJET**

Sub: Press Release - Blue Jet Healthcare for the Financial Results for the quarter ended June 30, 2025

Dear Sir / Madam,

In compliance with regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Press Release issued by Blue Jet Healthcare Limited.

We request you to take the same on your record.

Thanking you,

Yours faithfully,

For Blue Jet Healthcare Limited

Ms. Sweta Poddar **Company Secretary & Compliance Officer** (M. No.: F12287)

3/2, Milestone, Kalyan Murbad Road, Village Varap, P.O. Box No. 5, Shahad-421 103, Tel.: 91 251 2280283 Fax: +91 251 2280567

Plot No. B-12, C-4, E-2, MIDC, Industrial Area, Chemical Zone, Ambernath (W) 421501. Tel.: +91 8956363877/8956363878

K-4/1, Additional MIDC Road, Mahad Industrial Area, Mahad- 402309, Tel.: + 91 22 2207 5307 / 6192 / 1691 Fax : +91 22 2207 0294



Blue Jet Healthcare Limited Announces Q1 FY26 Results

Q1 Revenue at Rs. 3,548 mn; a jump of 117.8% YoY EBITDA Margins Climb to 34.1%; up by 693 bps YoY

Navi Mumbai, July 22, 2025: Blue Jet Healthcare Limited (BLUEJET) (BSE: 544009, NSE: BLUEJET) reported financial results for the quarter ended June 30, 2025, on July 22, 2025.

Financial Results – Q1 FY26

Particulars (Rs. Mn)	Q1 FY26	Q4 FY25	QoQ	Q1 FY25	YoY
Revenue from Operations	3,548	3,404	4.2%	1,629	117.8%
EBITDA	1,210	1,400	-13.6%	443	173.3%
EBITDA Margin	34.1%	41.1%	(701) bps	27.2%	693 bps
PAT	912	1,101	-17.2%	378	141.3%
PAT Margin	25.7%	32.3%	(664) bps	23.2%	251 bps

Commenting on results, Mr. Shiven Arora, Managing Director, Blue Jet Healthcare Limited, said: "Blue Jet Healthcare clocked a revenue of Rs. 3,548 million, a growth of 117.8% YoY with EBITDA coming in at Rs. 1,210 million. This was primarily driven by the ramp up in PI & API product categories. The robust growth, coupled with strong EBITDA margins, reflects our focus on operational efficiency and a solid business foundation.

Looking ahead, we remain confident in our growth strategy, driven by capacity expansions, enhanced R&D capabilities, and a robust pipeline of high-value products. We are committed to delivering long-term value to our stakeholders through consistent performance, innovation, and strategic investments."

Key Results Highlights:

Q1 FY26:

- ✓ Revenue from operations for Q1 FY26 stood at Rs. 3,548 mn which grew 4.2% QoQ compared to Rs. 3,404 mn in Q4 FY25; up 117.8% on YoY basis compared to Rs. 1,629 mn in Q1 FY25. This growth is mainly driven by higher sales in PI & API product category and gross margin of 48.4% in Q1 FY26.
- ✓ EBITDA for the quarter came at Rs. 1,210 mn, down 13.6% QoQ compared to Rs. 1,400 in Q4 FY25; up 173.3% YoY compared to Rs. 443 mn in Q1 FY25.
- ✓ EBITDA margin for the quarter came at 34.1% as compared to 41.4% in Q4FY25 down 701 bps; 27.2% in Q1 FY25, up 693 bps YoY.
- ✓ PAT for the quarter was at Rs. 912 mn, which degrew 17.2% QoQ compared to Rs.1,101 mn; up 141.3% compared to Rs. 378 mn in Q1FY25.
- ✓ PAT margin for the quarter came at 25.7% as compared to 32.3%, down 664 bps;
 23.2% in Q1 FY25, up 251 bps YoY.



✓ Reduction in QoQ is primarily attributable to a drop in gross margin to 48.4% in Q1 FY26 from 54.7% in Q4 FY25, driven by a shift in product mix and reduced inventory levels, resulting in lower overhead absorption during Q1 FY26.

ABOUT BLUE JET HEALTHCARE LIMITED:

Blue Jet Healthcare Ltd a specialty pharmaceutical and healthcare ingredient and intermediate company, operating under a contract development and manufacturing organization ("CDMO") business model. The company has specialized chemistry capabilities in contrast media intermediates and high-intensity sweeteners. They have built a long-term customer base with innovator and multi-national generic pharmaceutical companies, supported by multi-year contracts. They supply a critical starting intermediate and several advanced intermediates to three of the largest contrast media manufacturers in the world, including GE Healthcare, Guerbet, and Bracco. They also supply high-intensity sweeteners to several multi-national companies, including Colgate Palmolive (India) Limited and Unilever.

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and BLUEJET has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at Blue Jet I	Healthcare	Limited
----------------------------------	------------	---------

Sanjay Sinha, Deputy Chief Financial Officer sanjay.sinha@bluejethealthcare.com

Ernst & Young

Kunal Bhoite

kunal.bhoite@in.ey.com

Advait Bhadekar

Advait.bhadekar@in.ey.com

Registered Office

701,702, 7th Floor, Bhumiraj Costarica, Sector 18, Sanpada, Navi Mumbai Thane

400705, Maharashtra, India CIN: U99999MH1968PLC014154

ISIN: INEOKBH01020 NSE Code: BLUEJET BSE CODE: 544009

Website: www.bluejethealthcare.com